Cancer site distribution for subsequent malignancies according to sex
| . | Subsequent malignancy . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Men . | Women . | |||||||||||
| Second . | % . | Third . | % . | Fourth . | % . | Second . | % . | Third . | % . | Fourth . | % . | |
| Total* | 405 | 100 | 41 | 100 | 4 | 100 | 419 | 100 | 84 | 100 | 12 | 100 |
| All solid (nonbreast) | 297 | 73.3 | 37 | 90.2 | 3 | 75.0 | 184 | 43.9 | 32 | 38.2 | 5 | 41.7 |
| Lung | 103 | 25.4 | 11 | 26.8 | 0 | 0 | 37 | 8.8 | 5 | 6.0 | 0 | 0 |
| GI tract | 68 | 16.8 | 9 | 22.0 | 0 | 0 | 42 | 10.0 | 11 | 13.1 | 1 | 8.4 |
| Urogenital tract | 40 | 9.9 | 7 | 17.1 | 1 | 25.0 | 30 | 7.2 | 5 | 6.0 | 4 | 33.3 |
| Other | 86 | 21.2 | 10 | 24.3 | 2 | 50.0 | 75 | 17.9 | 11 | 13.1 | 0 | 0 |
| Breast | 2 | 0.5 | 1 | 2.4 | 0 | 0 | 184 | 43.9 | 46 | 54.8 | 7 | 58.3 |
| Leukemia and MDS | 29 | 7.2 | 2 | 5.0 | 0 | 0 | 18 | 4.3 | 0 | 0 | 0 | 0 |
| NHL | 57 | 14.1 | 1 | 2.4 | 1 | 25.0 | 22 | 5.3 | 5 | 6.0 | 0 | 0 |
| Unknown primary | 20 | 4.9 | 0 | 0 | 0 | 0 | 11 | 2.6 | 1 | 1.2 | 0 | 0 |
| . | Subsequent malignancy . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Men . | Women . | |||||||||||
| Second . | % . | Third . | % . | Fourth . | % . | Second . | % . | Third . | % . | Fourth . | % . | |
| Total* | 405 | 100 | 41 | 100 | 4 | 100 | 419 | 100 | 84 | 100 | 12 | 100 |
| All solid (nonbreast) | 297 | 73.3 | 37 | 90.2 | 3 | 75.0 | 184 | 43.9 | 32 | 38.2 | 5 | 41.7 |
| Lung | 103 | 25.4 | 11 | 26.8 | 0 | 0 | 37 | 8.8 | 5 | 6.0 | 0 | 0 |
| GI tract | 68 | 16.8 | 9 | 22.0 | 0 | 0 | 42 | 10.0 | 11 | 13.1 | 1 | 8.4 |
| Urogenital tract | 40 | 9.9 | 7 | 17.1 | 1 | 25.0 | 30 | 7.2 | 5 | 6.0 | 4 | 33.3 |
| Other | 86 | 21.2 | 10 | 24.3 | 2 | 50.0 | 75 | 17.9 | 11 | 13.1 | 0 | 0 |
| Breast | 2 | 0.5 | 1 | 2.4 | 0 | 0 | 184 | 43.9 | 46 | 54.8 | 7 | 58.3 |
| Leukemia and MDS | 29 | 7.2 | 2 | 5.0 | 0 | 0 | 18 | 4.3 | 0 | 0 | 0 | 0 |
| NHL | 57 | 14.1 | 1 | 2.4 | 1 | 25.0 | 22 | 5.3 | 5 | 6.0 | 0 | 0 |
| Unknown primary | 20 | 4.9 | 0 | 0 | 0 | 0 | 11 | 2.6 | 1 | 1.2 | 0 | 0 |
GI, gastrointestinal (esophagus excluded); MDS, myelodysplastic syndrome; NHL, non-HL.
Hematologic malignancies (other than leukemia, MDS, and NHL) are excluded.